The content on this site is intended for healthcare professionals only
ESMO 2017 highlights on managing difficult to treat cancers
ESMO 2017 roundup with Dr Bishal Gyawali (1/2)
ESMO 2017 roundup with Dr Bishal Gyawali (2/2)
Pembrolizumab falls short of endpoints in KEYNOTE 40
ARIEL3: Rucaparib as maintenance therapy in recurrent ovarian cancer patients
Initial results of inhibitor combination against breast and gynaecologic cancers
Patient empowerment and quality of life
Chemoradiation remains best treatment for locally advanced cervical cancer
LORELEI trial of letrozole and taselisib for ER positive breast cancer
Fertility-preserving procedures in BRCA mutation-positive breast cancer
Nivolumab and ipilimumab for metastatic kidney cancer
Biological insight in new drug combinations
BRIM8: Vemurafenib in high risk melanoma patients
Durvalumab in novel combinations for head and neck cancer
COMBI-AD: Dabrafenib plus trametinib in advanced melanoma
Expert commentary on melanoma immunotherapy latest
Vemurafenib for high risk melanoma patients
Dabrafenib plus trametinib for stage III mutant melanoma
Nivolumab vs ipilimumab for high risk melanoma patients
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection
The role of tumour marker testing in early diagnosis
The METRIC trial of trametinib, five years on
Patient perceptions of chemotherapy side effects differ over time and treatment
Treatment choices in thyroid cancer
Clinical advances in treating colorectal cancer
Impact of licensing and reimbursement discrepancies on cancer care in Europe and Canada
ABP 980, a biosimilar antibody for trastuzumab
New strategies in melanoma care
Real-world productivity of advanced gastric cancer patients
Abemaciclib for advanced breast cancer
Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancer
CheckMate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma
RANGE: docetaxel with or without ramucirumab for metastatic urothelial carcinoma
Chemotherapy then surgery no better than concomitant chemoradiation for advanced cervical cancer
MONARCH 3: Abemaciclib as initial therapy for patients with HR /HER2- advanced breast cancer
RANGE trial of ramucirumab for urothelial cancer
Small node-negative breast cancers may retain aggressive characteristics
Adaptive TONIC trial of nivolumab combinations for breast cancer
Panitumumab triplet therapy in colorectal cancer
Long term efficacy of denosumab for giant cell bone tumours
Returning to work after cancer
Financial and ethical safety in cancer care
STORM trial to identify genetic variability in metastatic breast cancer
The UNICANCER-NeoPAL study of letrozole and palbociclib in luminal cancer
Phase Ib/II trial of combination PD-1 therapy against kidney cancer
STAMPEDE: Abiraterone acetate plus prednisolone or docetaxel
Problems with care: a patients perspective
Reduced work ability in cancer survivors
Problems with survivorship care in Europe
Underprovision and inequality of specialised cancer care
Regorafenib versus lomustine for relapsed glioblastoma
Reviewing LORELEI, mindACT and ExteNET trials in breast cancer
PACIFIC trial of durvalumab for stage III NSCLC
Questioning the role of CT-scan in NSCLC post-surgery follow-up
Osimertinib suitable for first line EGFRm lung cancer
FLAURA study of osimertinib versus TKI for 1st line NSCLC
Follow-up on the IFCT-0302 trial
PACIFIC trial of durvalumab for lung cancer
ESMO 2017: CDK4/6 inhibitors from a patient’s perspective
